Orbital sarcoma with metastases at diagnosis: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Pediatr Blood Cancer. 2010 Jul 1;54(7):1045-7. doi: 10.1002/pbc.22434.

Abstract

We reviewed clinicopathologic features and treatment outcomes in seven patients diagnosed with Stage 4/Group IV orbital sarcoma and treated on IRSG protocols I-III. Three patients had embryonal rhabdomyosarcoma (RMS), and two patients each had alveolar RMS or unclassified sarcoma. Median age at diagnosis was 1.8 years (range 0.2-6.9 years). All patients had bone marrow involvement, including six with normal complete blood count at diagnosis. Cerebrospinal fluid was normal in six patients. Three patients survived >5 years, including one with local recurrence. In conclusion, further study is needed to determine necessity of bone marrow and CSF examination in orbital sarcoma patients.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Child
  • Child, Preschool
  • Cisplatin / therapeutic use
  • Combined Modality Therapy
  • Dactinomycin / therapeutic use
  • Doxorubicin / therapeutic use
  • Etoposide / therapeutic use
  • Female
  • Humans
  • Male
  • Neoplasm Metastasis / drug therapy
  • Neoplasm Metastasis / pathology*
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Staging
  • Orbital Neoplasms / mortality
  • Orbital Neoplasms / pathology*
  • Orbital Neoplasms / therapy
  • Radiotherapy
  • Sarcoma / mortality
  • Sarcoma / pathology*
  • Sarcoma / therapy
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • Dactinomycin
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cisplatin